PMC6489369_01
Imaging results. (a) Arterial phase computed tomography (CT) showing a tumor (white arrow) in segment 8 with early enhancement. (b) Equilibrium phase CT showing that the tumor is slightly hypodense. (c) Arterial phase ethoxybenzyl magnetic resonance imaging (EOB-MRI) showing early enhancement of hepatocellular carcinomas (HCCs) measuring 39 mm (white arrow) and 9 mm (arrowhead) in diameter in segment 8 of the liver. (d) Hepatocellular phase EOB-MRI showing hypointensity of the 2 tumors. (e) CT during arterial portography showing a perfusion defect in the 2 HCCs. (f, g) CT during hepatic arteriography (CTHA) showed hypervascular tumors in the early phase (f) and peripheral enhancement in the late phase (g). (h, i) Angiography showing both HCCs with enhancement during arteriography of A8 (h) and CTHA of A8 (i). (j, k) Enhanced CT findings 60 days after transcatheter arterial chemoembolization show sufficient lipiodol deposition in the 2 HCCs (j). However, a tiny lipiodol deposition-free area is also observed (red zone, k).
cro-0012-0289-g01.jpg
PMC6489369_03_cro-0012-0289-g01.jpg
F1
Abdominal dynamic CT on day 60 after TACE showed sufficient lipiodol deposition in the 2 HCCs in segment 8, but a tiny lipiodol deposit-free area remained (Fig. 1j, k).
PMC6489369_02
PMC6489369_03
Imaging results. (a) Arterial phase computed tomography (CT) showing a tumor (white arrow) in segment 8 with early enhancement. (b) Equilibrium phase CT showing that the tumor is slightly hypodense. (c) Arterial phase ethoxybenzyl magnetic resonance imaging (EOB-MRI) showing early enhancement of hepatocellular carcinomas (HCCs) measuring 39 mm (white arrow) and 9 mm (arrowhead) in diameter in segment 8 of the liver. (d) Hepatocellular phase EOB-MRI showing hypointensity of the 2 tumors. (e) CT during arterial portography showing a perfusion defect in the 2 HCCs. (f, g) CT during hepatic arteriography (CTHA) showed hypervascular tumors in the early phase (f) and peripheral enhancement in the late phase (g). (h, i) Angiography showing both HCCs with enhancement during arteriography of A8 (h) and CTHA of A8 (i). (j, k) Enhanced CT findings 60 days after transcatheter arterial chemoembolization show sufficient lipiodol deposition in the 2 HCCs (j). However, a tiny lipiodol deposition-free area is also observed (red zone, k).
cro-0012-0289-g01.jpg
PMC6489369_03_cro-0012-0289-g01.jpg
F1
Abdominal dynamic CT on day 60 after TACE showed sufficient lipiodol deposition in the 2 HCCs in segment 8, but a tiny lipiodol deposit-free area remained (Fig. 1j, k).
PMC6489369_04
Histopathological findings of the resected liver. (a) Photograph showing the removed section of the liver. Most of the tumor was successfully treated with transcatheter arterial chemoembolization, except for the small remaining viable hepatocellular carcinoma (HCC) (red zone). These lesions correspond with the computed tomography findings. (b) The viable tumor is a moderately differentiated HCC (hematoxylin and eosin staining).
cro-0012-0289-g02.jpg
PMC6489369_04_cro-0012-0289-g02.jpg
F2
TACE, except for the small remaining HCC where lipiodol deposition was insufficient. The smaller HCC which was 9 mm before TACE was completed (Fig. 2a, b).